http://dbpedia.org/ontology/abstract
|
Glycerol phenylbutyrate (USAN), trade name … Glycerol phenylbutyrate (USAN), trade name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body. It is an FDA-approved prescription drug in the US. It is approved for anyone over 2 months of age. It was developed by based on the existing drug Buphenyl, and received approval on February 1, 2013. Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales). In March 2015, Horizon Pharma acquired Hyperion Therapeutics and thus Raviciti.d Hyperion Therapeutics and thus Raviciti.
|
http://dbpedia.org/ontology/alternativeName
|
Ravicti
|
http://dbpedia.org/ontology/casNumber
|
611168-24-2
|
http://dbpedia.org/ontology/chEMBL
|
2105745
|
http://dbpedia.org/ontology/drugbank
|
DB08909
|
http://dbpedia.org/ontology/fdaUniiCode
|
ZH6F1VCV7B
|
http://dbpedia.org/ontology/pubchem
|
10482134
|
http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Glycerol_phenylbutyrate_skeletal.svg?width=300 +
|
http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/glycerol%20phenylbutyrate +
|
http://dbpedia.org/ontology/wikiPageID
|
38979808
|
http://dbpedia.org/ontology/wikiPageLength
|
4846
|
http://dbpedia.org/ontology/wikiPageRevisionID
|
1003129915
|
http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Urea_cycle_disorder +
, http://dbpedia.org/resource/Ammonia +
, http://dbpedia.org/resource/Oral_administration +
, http://dbpedia.org/resource/Buphenyl +
, http://dbpedia.org/resource/Hyperion_Therapeutics +
, http://dbpedia.org/resource/Horizon_Pharma +
, http://dbpedia.org/resource/Category:Prodrugs +
, http://dbpedia.org/resource/United_States_Adopted_Name +
|
http://dbpedia.org/property/atcPrefix
|
A16
|
http://dbpedia.org/property/atcSuffix
|
AX09
|
http://dbpedia.org/property/c
|
33
|
http://dbpedia.org/property/casNumber
|
611168
|
http://dbpedia.org/property/chembl
|
2105745
|
http://dbpedia.org/property/chemspiderid
|
8657541
|
http://dbpedia.org/property/drugbank
|
DB08909
|
http://dbpedia.org/property/h
|
38
|
http://dbpedia.org/property/iupacName
|
123
|
http://dbpedia.org/property/legalEu
|
Rx-only
|
http://dbpedia.org/property/legalUs
|
Rx-only
|
http://dbpedia.org/property/licenceEu
|
yes
|
http://dbpedia.org/property/o
|
6
|
http://dbpedia.org/property/pregnancyUs
|
C
|
http://dbpedia.org/property/pubchem
|
10482134
|
http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Oral_administration +
|
http://dbpedia.org/property/smiles
|
C1=CC=CCCCCOCCOCCCCC3=CC=CC=C3
|
http://dbpedia.org/property/stdinchi
|
1
|
http://dbpedia.org/property/stdinchikey
|
ZSDBFLMJVAGKOU-UHFFFAOYSA-N
|
http://dbpedia.org/property/tradename
|
Ravicti
|
http://dbpedia.org/property/unii
|
ZH6F1VCV7B
|
http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Gastrointestinal-system-drug-stub +
, http://dbpedia.org/resource/Template:Cascite +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Infobox_drug +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Other_alimentary_tract_and_metabolism_products +
|
http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Prodrugs +
|
http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Medication +
|
http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Glycerol_phenylbutyrate?oldid=1003129915&ns=0 +
|
http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Glycerol_phenylbutyrate_skeletal.svg +
|
http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Glycerol_phenylbutyrate +
|
owl:sameAs |
http://dbpedia.org/resource/Glycerol_phenylbutyrate +
, http://sr.dbpedia.org/resource/Glicerol_fenilbutirat +
, http://sh.dbpedia.org/resource/Glicerol_fenilbutirat +
, https://global.dbpedia.org/id/X7aC +
, http://he.dbpedia.org/resource/%D7%92%D7%9C%D7%99%D7%A6%D7%A8%D7%95%D7%9C_%D7%A4%D7%A0%D7%99%D7%9C%D7%91%D7%95%D7%98%D7%99%D7%A8%D7%90%D7%98 +
, http://www.wikidata.org/entity/Q15322709 +
, http://rdf.freebase.com/ns/m.0sgf9w6 +
|
rdf:type |
http://dbpedia.org/ontology/Drug +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/CausalAgent100007347 +
, http://dbpedia.org/class/yago/Drug103247620 +
, http://dbpedia.org/class/yago/Agent114778436 +
, http://dbpedia.org/class/yago/Substance100020090 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://www.wikidata.org/entity/Q8386 +
|
rdfs:comment |
Glycerol phenylbutyrate (USAN), trade name … Glycerol phenylbutyrate (USAN), trade name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body. It is an FDA-approved prescription drug in the US. It is approved for anyone over 2 months of age. It was developed by based on the existing drug Buphenyl, and received approval on February 1, 2013. Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales). In March 2015, Horizon Pharma acquired Hyperion Therapeutics and thus Raviciti.d Hyperion Therapeutics and thus Raviciti.
|
rdfs:label |
Glycerol phenylbutyrate
|